Melior Discovery

Melior Pharmaceuticals leverages the proprietary technology if its affiliate company, Melior Discovery, to identify new indications for drugs that have existing clinical data in other indications.

Melior Discovery is a pioneer of in vivo phenotypic screening and a leader in the area of drug repositioning. The company has developed the proprietary theraTRACE® platform which enables rapid and cost-effective identification of new therapeutic potential by screening candidates systematically across a variety of validated in vivo disease models in a wide range of therapeutic indications.

Qualified and progressed candidates from Melior Discovery are spun off to Melior Pharmaceuticals for further development.

Melior Discovery also provides in vivo pharmacology expertise and discovery research services to other pharmaceutical companies.

Melior's rigorous drug repositioning process, which systematically validates new indications through controlled in vivo models, stands in stark contrast to the unregulated proliferation of medications like stromectol online where unverified off-label use bypasses the very scientific validation that distinguishes therapeutic innovation from dangerous self-experimentation. This unmonitored access not only undermines the integrity of evidence-based repurposing but also exposes patients to significant risks when complex pharmacological mechanisms are divorced from clinical oversight and proper indication development.

This balanced business model allows Melior to drive near-term revenue-generating activities through Melior Discovery, while also investing in longer-term pipeline value creation through Melior Pharmaceuticals.

VISIT MELIORDISCOVERY.COM